Effects of Telerehabilitation Versus Clinical Rehabilitation on Chemotherapy Induced Peripheral Neuropathy

Launched by RIPHAH INTERNATIONAL UNIVERSITY · Nov 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different types of rehabilitation on patients experiencing nerve pain due to chemotherapy, a condition known as Chemotherapy-Induced Peripheral Neuropathy (CIPN). The researchers want to see whether telerehabilitation, which is rehabilitation done over the internet, is just as effective as traditional clinical rehabilitation, which takes place in a physical location. They will look at how each method affects pain, physical ability, and overall quality of life for women who have undergone specific chemotherapy treatments for breast cancer.

To be eligible for this trial, participants must be female, aged between 45 and 75, and have had certain types of chemotherapy. They should be expected to live for at least six months and have a specific level of nerve pain as measured by a questionnaire. However, women with a history of nerve problems or other health issues that could affect their nerves are not eligible. If you or someone you know meets these criteria, participants can expect to engage in either telerehabilitation or clinical rehabilitation programs, aimed at improving their symptoms and overall well-being. The trial is not yet recruiting, but it could provide valuable insights into better treatment options for patients facing similar challenges.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female patients with breast cancer.
• • Patients of age between 45 to 75years.
• • Patient expected to survive for 6 month or more.
• • Patient after specific chemotherapy such as taxanes(paclitaxel),vinca alkaloids(vinorelbine),bortezomib, lenalidomide and platinum-based.
• • Patient with Stage 1 to 3.
• • Patients have prior history of mechanical nerve entrapment without clinical symptoms (carpal tunnel syndrome) were included.
• • Patient who sustained grade 3 and 4 of European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20).
• Exclusion Criteria:
• • Patients with history of peripheral neuropathy.
• • Participants are excluded if they had comorbid conditions causing peripheral neuropathic symptoms (including previous chemotherapy or diabetes or alcohol abuse and non-alcoholic liver diseases.
• • Patients not scheduled for one of the aforementioned taxane-based regimens.
• • Patients with vitamin D or B12 deficiency.
• • Non-ambulatory Patients.
• • Patients reluctant to practice exercise program.
• • Patient have impaired visual or vestibular system and presence of bone or any kind of central nervous system involvement , including cancer.